Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 6, p. 1, doi. 10.1002/hon.70001
- By:
- Publication type:
- Article
Works matching AU Ribakovsy, Elena
Results: 4
1
2
Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 12, p. e929, doi. 10.1016/j.clml.2021.07.006
- By:
- Publication type:
- Article
3
The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
- Published in:
- Annals of Hematology, 2014, v. 93, n. 8, p. 1297, doi. 10.1007/s00277-014-2043-y
- By:
- Publication type:
- Article
4
The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
- Published in:
- 2008
- By:
- Publication type:
- journal article